Compare Citius Pharmaceuticals Inc (CTXR) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while iShares 10 20 Year Treasury Bond ETF trades at $98.47. The key difference: iShares 10 20 Year Treasury Bond ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | TLH | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | Fixed Income |
52-Week High | $1.82 | $105.36 |
52-Week Low | $0.53 | $97.13 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
TLH stock trades at $97.98, down 0.53% today, with a bearish technical signal from moving averages but bullish oscillators. The company has announced dividends for H1-26 and H2-26, yet key financial ratios are unavailable. Recent news highlights broader market volatility from Fed policy uncertainty and geopolitical tensions.
The outlook is cautious due to missing fundamental data and bearish technicals. Risks include macroeconomic headwinds and lack of visibility on earnings. Investment opportunity hinges on future financial disclosures and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
